Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

SMYD3 leads to the methylation of TP53. 1 / 1

| 1

➶

reach

"Although the mechanism linking these methyltransferases and CK is unknown, it noteworthy that SMYD2 may act as an oncogene by promoting the methylation of p53 and of the retinoblastoma tumor suppressor protein (RB) [56–57], and that SMYD3 promotes MAP3K2 methylation, inducing genomic instability by activation of Ras/Aurora kinase A-driven mechanisms [55, 58–59]."

30344950

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...